Orna Therapeutics Announces Acquisition of ReNAgade Therapeutics


We’re rapidly and relentlessly advancing transformational RNA medicines.

See the headlines our progress has inspired.

February 2024

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Cambridge, Mass., February 27, 2024 – ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer. 

“Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “In this newly created position, Joe will advise the company on research strategy and direction as well as help drive our lead programs towards development milestones. We are very excited to welcome him to the team.”  

“ReNAgade is leading the industry in its efforts to transcend the boundaries of RNA medicine,” said Dr. Bolen. “I am thrilled to join the company and undertake an important role in shaping research plans as we work together to translate ReNAgade’s multi-modal RNA platform into therapeutic advances for patients with high unmet medical needs.”  

Dr. Bolen brings more than 45 years of industry and research experience to ReNAgade. He is an Executive Partner at MPM BioImpact and was formerly Chief Scientific Officer at PureTech Health. Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer. Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX) and Bristol Myers Squibb. He began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Joe earned a Ph.D. in Immunology and conducted his postdoctoral training in molecular virology at Kansas State University Cancer Center. He graduated from the University of Nebraska with a B.S. in Microbiology and Chemistry. 

About ReNAgade Therapeutics 

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines. 

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines. 

ReNAgade Therapeutics—RNA Without Limits 

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com 

Investor Relations Contact:

Emily Brabbit, Argot Partners
(212) 600-1902

Media Relations Contact:

Sarah Sutton, Argot Partners
(212) 600-1902

“RNA without limits”, “Deliver-Code-Edit-Insert” are trademarks of ReNAgade Therapeutics, Inc.